- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Luis A. Diaz Foresees Mismatched Repair Testing Implementation in Cancer Treatment
Luis A. Diaz, Jr, MD, associate professor of oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discovered that patients with high mutational burden with mismatched repair responded well to checkpoint inhibition of PD1.
uis A. Diaz, Jr, MD, associate professor of oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discovered that patients with high mutational burden with mismatched repair responded well to checkpoint inhibition of PD1. For colon cancer and perhaps for additional cancers such as pancreatic, lung, and ovarian, Dr Diaz predicts that mismatched repair testing will change the course of cancer treatment in the coming years.
L
“My suspicion is that this will become standard of care in the near future for colon cancer. And that will demand that mismatched repair testing be a part of the standard of care for those patients,” Dr Diaz said. “And I suspect that up front, when you get diagnosed with advanced colon cancer, you’re going to get mismatched repair testing.”
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center is now in collaboration with Merck, which Dr Diaz said is in the beginning stages of opening 2 new studies focused on patients who failed all therapy and on patients who are newly diagnosed in an effort to compare which standard of care works more effectively.
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
